No Data
No Data
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Biopharma's Trem-cel Therapy Shows Promise With Positive Patient Dosing and Upcoming Data Presentation
Vor Biopharma Is Maintained at Outperform by Baird
Express News | HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Vor Biopharma Analyst Ratings
Barclays Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $3
No Data
No Data
Benjamin’s : Why this very good company with great balance sheets. Better then most so much in pipeline great news after news it continues to go down… this is wrong shorts that destroy good companies. BS should be illegal all the naked shorts etc. most cases you can track easily. I have zero issues with shorts destroying companies that are shit. example muln… yeah short companies/ sorry scam companies.
Krystian 1983 :